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Abstract 
Background: To identify in vivo new cardiac binding sites of serum response factor (SRF) in genes and to study the response of these 
genes to mild over-expression of SRF, we employed a cardiac-specific, transgenic mouse model, with mild over-expression of SRF 
(Mild-O SRF Tg).
Methodology: Microarray experiments were performed on hearts of Mild-O-SRF Tg at 6 months of age. We identified 207 genes that 
are important for cardiac function that were differentially expressed in vivo. Among them the promoter region of 192 genes had SRF 
binding motifs, the classic CArG or CArG-like (CArG-L) elements. Fifty-one of the 56 genes with classic SRF binding sites had not 
been previously reported. These SRF-modulated genes were grouped into 12 categories based on their function. It was observed that 
genes associated with cardiac energy metabolism shifted toward that of carbohydrate metabolism and away from that of fatty acid 
metabolism. The expression of genes that are involved in transcription and ion regulation were decreased, but expression of cytoskeletal 
genes was significantly increased. Using public databases of mouse models of hemodynamic stress (GEO database), we also found that 
similar altered expression of the SRF-modulated genes occurred in these hearts with cardiac ischemia or aortic constriction as well.
Conclusion and significance: SRF-modulated genes are actively regulated under various physiological and pathological conditions. 
We have discovered that a large number of cardiac genes have classic SRF binding sites and were significantly modulated in the Mild-
O-SRF Tg mouse hearts. Hence, the mild elevation of SRF protein in the heart that is observed during typical adult aging may have a 
major impact on many SRF-modulated genes, thereby affecting cardiac structure and performance. The results from our study could 
help to enhance our understanding of SRF regulation of cellular processes in the aged heart.
Keywords: SRF modulated genes, SRF binding sites, mouse heart, mild-SRF over-expression, gene expression; striated muscle.Zhang et al
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Introduction
It is well appreciated that the mammalian adult heart 
undergoes a number of changes with advancing age.1–3 
Recent studies indicate that one of the key transcrip-
tion factors, serum response factor (SRF), plays an 
important role in the regulation of cardiac genes dur-
ing development and adult aging.4–7 SRF is a mem-
ber  of  the  MADS  (MCM1,  Agamous,  Deficiens, 
SRF) family of transcription factors that regulates the 
genes that are usually considered to be immediate-
early  genes  and  muscle-related  genes.8,9  SRF  also 
serves to regulate cell proliferation, cell size, and cell 
survival.7,10–12
SRF modulates genes by binding to the cognate 
response element, the serum response element (SRE), 
which contains a consensus sequence of CC(A/T)6GG 
also known as the CArG box.13–16
In addition, SRF can also regulate the gene pro-
moters containing the CArG-like (CArG-L)   elements, 
which have only a single base mismatch from the 
classic CArG box.8,17 It has been estimated that hun-
dreds  of  SRF-modulated  genes  that  contain  CArG 
and/or CArG-L motifs may exist in both the mouse 
and  human  genomes.18  However,  to  identify  those 
genes  with  CArG  or  CArG-L  elements  remains  a 
challenge.
The level of SRF expression increases by approx-
imately 20% from the age of 3 months to 20 months 
(from young adulthood to early senescence) in rodent 
hearts.4,6 It is plausible that this increased SRF might 
contribute to altered expression of SRF-modulated 
genes,  thereby  affecting  cardiac  function  in  aged 
mice. In our previous study, we reported the gen-
eration and characterization of transgenic mice with 
mild cardiac-specific SRF overexpression of approx-
imately  40%–50%.6  Mild  overexpression  of  SRF 
produced cardiac changes in young adult transgenic 
mice similar to that observed in normal senescence. 
By 6 months of age, the hearts of these young adult 
transgenic  mice  had  changes  that  usually  appear 
later, at around 20 months or older, which include 
mild  cardiomyocyte  hypertrophy,  cardiac  fibrosis 
and mildly increased left ventricular wall thickness. 
The  cardiac  functional  changes,  including  a  20% 
reduction in early diastolic LV filling (peak E) and 
a 35% decline in peak E-to-peak-A (late diastolic 
filling) ratio, are similar to those seen clinically in 
late life as part of typical human adult   myocardial 
aging.6,19,20  It  appeared  likely  that  SRF-modulated 
genes may have contributed to the cardiac phenotype 
in this model of myocardial aging.6
To  determine  the  response  in  vivo  of  potential 
SRF-modulated  genes,  we  examined  the  cardiac 
gene profile of the Mild-O-SRF Tg. We found that 
the expression of 207 cardiac genes was significantly 
altered in the transgenic mice compared to their non-
transgenic littermates. Bioinformatics analysis of the 
promoter of 207 genes showed that 93% of the genes 
in the 6 month old Mild-O-SRF Tg hearts had CArG 
or CArG-L elements. These genes encoded a broad 
spectrum of proteins involved in multiple functions 
including metabolism, cytoskeleton, transcription and 
translational regulation, extracellular matrix, ion trans-
port, stress response, as well as protease and protease 
inhibitors.
Experimental Procedures
Transgenic mouse with mild  
cardiac-specific overexpression  
of SRF (Mild-O-SRF Tg)
The  generation  and  characterization  of  transgenic 
mice  with  mild  cardiac-specific  overexpression  of 
SRF was previously reported.6 At 6 months of age, 
the Mild-O-SRF Tg mice manifested cardiac changes 
with  mild  diastolic  impairment,  suggestive  of  an 
“aged heart”.6 These alterations included mild fibro-
sis and hypertrophy, with preserved systolic function, 
but impaired diastolic function. Therefore, 6-month-
old transgenic and non-transgenic mice were used in 
this study. The studies were conducted with Institu-
tional Review Board approval from the University 
of Arkansas for Medical Sciences, and in accordance 
with the NIH Guiding Principles for Research Involv-
ing Animals.
Total RnA isolation, Genechip 
hybridization and preliminary  
data analysis
Total RNA was isolated from the cardiac ventricles 
of the transgenic and non-transgenic mice as previ-
ously described.21 The total RNA preparations were 
then  subjected  to  a  purification  procedure  using 
RNeasy Mini Spin Columns (Qiagen). The total RNA effect of mild-overexpression of SRF on cardiac gene expression in vivo
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  preparations from five animals were pooled per group. 
Each   sample from one group was hybridized to an 
  independent  GeneChip  MGU74Av2  (  Affymetrix). 
The  GeneChip  hybridization  and  preliminary  data 
analysis were performed according to the standard 
procedures  at  the  Genomic  Center  at  Beth  Israel 
  Deaconess Medical Center in Boston.22
Microarray data analysis
The microarray data analysis and data interpretation 
were performed using ArrayTrack.23 A list of dif-
ferentially expressed genes (DEGs) were identified 
using a t-test with a combination of cut off P-value 
(P , 0.05) and fold change (FC . 2). The Array-
Track  Gene  Ontology  (GO)  tool  Gene  Ontology 
for   Function Analysis (GOFFA) was subsequently 
applied to the DEGs for biological interpretation.24,25 
The statistical significance of a GO term was deter-
mined using Fisher’s Exact Test. Furthermore, the 
GOPath and TreePrune in GOFFA were also used 
to  identify  significant  biological  functions  based 
on  the  DEGs.  In  addition  to  GOFFA  analysis, 
DEGs  were  also  analyzed  in  canonical  pathway 
maps using GeneGo MetaCore. Experimental data 
are  visualized  as  red/blue  thermometers  pointing 
up/down, and signifying up/down-regulation of the 
map objects.
The microarray data is MIAME compliant and has 
been deposited in GEO database with ACCESSION 
number GSE19874.
Validation of the array data:  
real time PcR
Validation of the Affymetrix data was performed by 
qPCR analysis with the ABI PRISM 7700 Sequence 
Detection  System  (Applied  Biosystem,  CA)  using 
standard procedures. All microarray results that were 
changed  $2  fold  were  validated  by  real-time  RT 
PCR. The primers used in experiments are enumer-
ated in the table above.
To allow comparison of qRT-PCR values, the con-
centration of cDNA in each sample was adjusted to 
yield similar amounts of PCR product when amplified 
by primers for 18S. The 18S reaction was performed 
using standard curves representing 5, 1.25, 0.31, and 
0.08 ng/µl of the pooled cDNA. Standard curves were 
generated for all other targets using pooled RT-PCR 
products at 80, 20, 5 and 1.25 ng/µl. Relative stan-
dard curve method is used to calculate the amplifica-
tion difference between the samples.
Gene Forward sequence Reverse sequence
B4Galnt1 TcGcTGAcGAcAGTGAcAAAc TGccGAAGGGcATGAAGTAG
Apod TGGccAccGATTATGAAAAcT ccAcATGGAAGAGccAGAAGA
Pfkp TcAGcccTGcAccGAATTAT cATcAccTccAGGAcGAAGGT
Acot9 cATATGAAcTTGcATGGGcTAcTG AAccAAcTTcAAcAGGcTTcTGA
Slc27a1 GGAcGccAGTAGTGGTATATGcT GcGGAAcAGGTTGGcTAcAG
Lipc ccTcAGcAcccGGAAAcA cAcccGTGGATGATcATGATAA
coasy ccGTGGGTGGcAcTTTTG GcTccTGGGccAGTAcAcAT
Pafah1b3 GTTGTGcTGGGccTGcTT ccTGTcGGTTTTTcTcTcGAA
Pgk2 TGcTAAAGGAAccAAAGcTcTcAT GGcGcAGcAAGTAGcAGTATcT
Apoa1 AGAGcAAcccTAccTTGAAcGA TGGcTTTcTcGccAAGTGT
Maoa cccATTccGTGGTGcATT cATccATTGTccTccAcAGGTT
cyp2b10 GAAAGTccAAAAGGAGATTGATcAG cATTTTGGTGcGGTcATcAAG
cyp3a16 cTGcAGGAGGAGATcGATGAG ccATcGccATcAcGGTATc
cyp3a11 AAcTGcAGGATGAGATcGATGAG TTcATTAAGcAccATATccAGGTATT
Uox TcAAAcAcGTccATGcATTcA TTcTcATcTGcTccAccTcAcA
Myl1 TGAAcAGTTTcTGcccATGATG cAGAcccTcAAcGAAATcTTcATA
Anxa10 GAcATGcTGATTGAcATccTAAcAc cATGcTcTGATAGGTcccAGcTA
Rab8b GGcGAAGAcGTAcGATTATcTGT GTTGAAGGcGTccTcTGAGAA
Acta2 TccTGAcGcTGAAGTATccGATA GGTGccAGATcTTTTccATGTc
casq1 TTcTTAGATcccAGcccAGTTc GTGGcGGGAAGAGAAAcAGA
Actn1 ccTcccGGATGcAGAcAA TGGAcGATcTTGGAcAcTTcAT
epb4.2 TcAcGGcAATGGcAAGGT cGGTTTAccAATGGccATATTT
Dstn TGAAGcAGGTAccATGGATGAc GccATGccTGTGATGTTAAcAZhang et al
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207 genes with ≥ 2 fold
change in Mild-SRF Tg
BLAST against mouse genome
TESS analysis of 10-Kb promoter region of
  each gene for CArG and CArG-like motifs
Results confirmed
Classic CArG
n = 56
CArG-like
n = 136
No CArG or
CArG-like n = 9
Insufficient data
n = 6
Figure 1. Flow diagram showing the method of defining classic CArG 
and cArG-like elements in 207 SRF-modulated genes in response to 
mild-SRF  overexpression  in  vivo.  The  sequence  of  each  gene  was 
BLAST-ed against the mouse genome and the promoter of each gene 
was identified. The classic CArG and/or CArG-like sequences in the pro-
moter region were identified by Transcription Element Search (TESS) 
software and confirmed by LALIGN software and visual comparison (see 
text in methods section for details).
Analysis of SRF binding sites:  
the classic cArG and cArG-like  
motifs in the gene promoter
The  criteria  for  the  classic  CArG  motif  is  a  10-bp 
element  that  has  the  sequence  CC(A/T)  6GG  and 
CArG-like element has a single base mismatch from 
its classic counterpart.8 Briefly, the mRNA sequences 
were obtained from the RefSeq database for most of the 
207 genes; the mRNA sequences were also obtained 
from GenBank database for several genes that did not 
have reference sequences in the RefSeq database as of 
September 2007. The reference mRNA sequences were 
submitted to BLAST for comparison with the mouse 
genomic DNA sequence in the mouse genome data-
base. After noting the orientation of the alignment, the 
appropriate 10-Kb genomic DNA sequence upstream 
from the transcription start point corresponding to the 
promoter region of each gene was isolated and   analyzed 
using a web-based bioinformatics tool TESS at http://
www.cbil.upenn.edu/cgi-bin/tess/tess.  Because  TESS 
results are model-based, the potential CArG and CArG-
like sequences were verified by both using LALIGN 
(http://www.ch.embnet.org/software/LALIGN_form.
html) and visual confirmation (Fig. 1).
comparison of differentially expressed 
genes in the Mild-O-SRF Tg mice  
with other mouse models
To ascertain if our data compared well with other 
models of aging or cardiac ischemia, we looked at 
27 other GEO microarray data bases of aging and 
heart available online at the Gene Expression Omni-
bus  (GEO,  http://www.ncbi.nlm.nih.gov/geo/).  The 
GEO  database  was  searched  for  expression  data 
from experiments using mouse hearts on the Affyme-
trix MGU74aV2 chip. The 27 gene expression data 
sets  were  also  analyzed  for  differential  expression 
by fold-change and P-value (two-tailed T-test). The 
lists  of  differentially  expressed  genes  were  com-
bined and filtered with our list of 207 differentially 
expressed  SRF-modulated  genes.  Fold-change  in 
gene   expression was examined at 2-fold change and 
P-value was tested at P , 0.05.
Results
Mild overexpression of SRF altered 
many cardiac genes in vivo
To  examine  the  impact  of  mild  overexpression  of 
SRF  on  cardiac  gene  expression  and  to  explore 
the    potential  mechanism  underlying  the  functional 
changes resembling cardiac aging, microarray anal-
ysis  was  performed  using  mouse  hearts  from  the 
6-month-old  transgenic  mice  and  non-transgenic 
  littermates. The expression of 207 cardiac genes was 
significantly altered in the transgenic mice compared 
to non-transgenic littermates (Tables 1 and 2). We 
consider all 207 of these genes as “SRF-modulated 
genes”. Among them, 65% (135 of 207) of the genes 
were down-regulated, whereas 35% (72 of 207) of 
the genes were up-regulated, indicating that increased 
SRF expression repressed the expression of a major-
ity of cardiac genes (Fig. 2).
Most of the genes that were significantly 
impacted by mild overexpression  
of SRF contained cArG and/or  
cArG-like elements
To  examine  whether  SRF  activated  or  repressed 
genes  that  contain  CArG  and/or  CArG-like  ele-
ments  within  their  promoter  regions,  we  further 
analyzed transcriptional sites within the 10-Kb pro-
moter region in each of the 207 genes. The classic 
CArG element was defined as a 10-bp DNA sequence 
with “CC(A/T)6GG”. The “CArG-like” element was 
defined as a 10-bp sequence with only one substitu-
tion from the consensus sequence. As shown in the 
flow  diagram  in  Figure  1,  CArG  and  CArG-like effect of mild-overexpression of SRF on cardiac gene expression in vivo
Gene Regulation and Systems Biology 2011:5  45
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Table 2. Functional categories of SRF-modulated genes. each of the 207 SRF-modulated genes was assigned to one of 
12 categories. 56 genes contained classic cArG elements, 136 genes contained cArG-like elements, 15 genes did not 
have both elements, or there are not sufficient data to show that they had either element.
Category CArG CArG-like Without CArG/CArG-like*,   
or insufficient data
  1. energy metabolism 4 10 1
  2. Xenobiotic metabolism 4 7
  3. cytoskeleton 8 9
  4. Transcription and translation 7 20 3
  5. extracellular matrix 2 10
  6. Stress response 2 10
  7. Signaling proteins 7 24 2
  8. Proteases, and protease inhibitors 5 6
  9. complement and coagulation 0 6 1
10. ion transport 3 8
11. immune response 1 6 4
12. Other proteins 13 20 4
Total 56 136 15
14.07%
5.19%
6.67% 8.15%
19.26% 13.89%
8.33%
5.56%
20.83%
4.17%
2.78%
5.56%
5.56%
15.28%
2.78%
15.28%
5.19%
5.19%
5.93%
5.93%
4.44%
13.33%
6.67%
65%
35%
8.15% Energy metabolism
Xenobiotic metabolism
Cytoskeleton and cellular function
Transcription and translation regulation
Extracellular matrix and cell adhesion
Stress response
Signaling proteins
Proteases and protease inhibitors
Complemant and coagulation
Ion transport
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Other proteins
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5.19%
14.07%
4.44%
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0.00%
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Figure 2. A Pie chart schematic showing percentage distribution of 207 SRF-modulated genes in response to mild-SRF overexpression in vivo. The pie 
chart in the center depicts percent distribution of all the 207 genes: 35% (72 of 207) of the genes are increased (in red), and 65% (135 of 207) of the genes 
are decreased (in green). The smaller pie charts on the right (shades of red) and left (shades of green) show distribution of the functional categories of genes 
within the increased or decreased subdivision. The percentage distribution is marked next to each category on the pie chart as well as in the legend.
  elements within the 10-Kb promoter region of each 
gene was analyzed and verified by using software 
program TESS  and  LALIGN.26,27 The  existence  of 
one or more of either a CArG or a CArG-like element 
in the promoter sequence of each of the 207 genes 
was then confirmed by visual inspection.
Most of the genes that were significantly impacted 
by mild overexpression of SRF contained CArG and/
or CArG-like elements. As shown in Tables 1 and 2, 
approximately 93% (192 of 207) of the cardiac genes 
that  responded  significantly  to  SRF  overexpres-
sion  contained  CArG  and/or  CArG-like  elements. effect of mild-overexpression of SRF on cardiac gene expression in vivo
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Roughly 29% (56 of 192) of the SRF-  modulated genes 
contained at least one classic CArG element, while 
71% (136 of 192) of them had at least one CArG-
like   element. Of those 56 genes with a classic CArG 
  element, approximately 79% (44 of 56) also contained 
at least one CArG-like element. Many of these genes 
have not been previously reported as SRF-modulated 
genes (Table 1 and Table S1). In addition, mild over-
expression  of  SRF  repressed  65%  (124/192)  and 
activated 35% (68/192) of the SRF-modulated genes 
(Fig. 2). These data indicate that SRF both represses 
and activates genes containing CArG and/or CArG-
like elements.
Mild overexpression of SRF affected 
SRF-modulated genes in multiple 
functional categories
To assess the significance of altered expression of 
SRF-modulated genes on cardiac function, the 207 
SRF-modulated genes were grouped into 12 catego-
ries according to their function and Gene Ontology 
(GO) term. They are energy metabolism, xenobiotic 
metabolism, cytoskeleton, transcription and transla-
tion  regulation,  extracellular  matrix  (ECM),  stress 
response, signaling proteins, protease and protease 
inhibitors, complement and coagulation, ion transport, 
immune response as well as other proteins (Table 2, 
Figs. 2, 3 and 4). The 192 genes that contain CArG 
and/or CArG-like elements were distributed among 
all of the 12 categories (Table 2). The 56 genes that 
contain at least one classic CArG element were also 
found in 11 of the 12 categories (Table 2). Mild over-
expression of SRF down-regulated a majority of the 
genes in 10 categories, but up-regulated most of the 
genes  in  the  category  of  cytoskeleton  and  cellular 
function (Table S1).
It  was  found  that  mild  overexpression  of  SRF 
changed the expression of genes regulating energy 
metabolism.  For  example,  phosphofructokinase,  a 
key enzyme that controls the pace of glycolysis was 
elevated over 2-fold. The SRF-modulated genes that 
regulate fatty acid metabolism were down-regulated. 
Solute carrier family 27 (slc27a1), which catalyzes 
the  transfer  of  long-chain  fatty  acids  across  the 
plasma membrane, was down 2-fold.28 Lipase, which 
catalyzes the rate-limiting step in adipose tissue lipol-
ysis, was down 2-fold.29 Elongase 2 (Elovl2), which 
performs the first regulatory step (condensation) in 
the elongation cycle in fatty acid synthesis, was down 
5-fold.30 Esterase 1 (Es-1), which hydrolyzes a variety 
of esters including fatty acid esters of estradiol, was 
down 17.5-fold. Coenzyme A synthase was decreased 
2.2-fold.
Our  data  also  revealed  that  SRF  impacted  the 
genes  involved  in  transcriptional  and  translational 
regulation. The genes that were up-regulated include 
distal-less  homeobox  5  (4.8-fold),  activating  tran-
scription  factor  3  (ATF3,  up  4.5-fold),  TATA  box 
binding  protein  (TBP,  up  3.8-fold),  and  four  and 
a half lim domains 1 (Fhl1, up 3-fold), Id2, which 
forms heterodimer with other HLH proteins, was up 
2.3-folds.  The  down-regulated  genes  include  Six3 
(down 2-fold), Gtf3c4 (down 2.6-fold), Lhx8 (down 
2-fold), Hmx1 (down 2.2-fold), Sp4 (down 2.6-fold), 
and E2F3 (down 5-fold). The proprotein convertase 
(PCSK5),  which  mediates  post-translational  endo-
proteolytic processing for several integrin alpha sub-
units, was down 2.7-fold.
An equal number of genes in the ECM category 
were  up-regulated  and  down-regulated.  Mild  SRF 
overexpression not only changed the expression of 
cytoskeletal genes but also changed the expression 
of  many  genes  in  other  functional  categories.  For 
instance,  several  ECM  genes  were  up-regulated, 
including  type  I  collagen,  fibulin  and  biglycan. 
  Serpine1/PAI-1,  which  inhibits  the  degradation  of 
ECM proteins, was also up 2.9-fold. Changes were 
also observed in genes that play a regulatory role in 
cardiac hypertrophy and fibrosis, such as TGF- beta3 
(up 3-fold); connective tissue growth factor (CTGF), 
which promotes fibroblast proliferation and myocyte 
growth, was increased by 4-fold. GDF15, a mem-
ber  of  TGF-beta  superfamily  and  a  potential  bio-
marker for cardiac disease, was increased 14-fold.31 
  Periostin, which regulates collagen I fibrillogenesis, 
was elevated over 4-fold.32,33 Annexins (ANXs) are a 
large group of calcium-binding proteins participating 
in diverse important biological processes.34,35 In the 
mild-SRF transgenic mouse heart, annexin a10 was 
increased by more than 30-fold.
Alteration was also observed in the expression of 
genes involved in proteolysis. Ubiquitin specific pep-
tidase 29 (USP29) was increased 3.7-fold. Dipeptidyl 
peptidase 7 (DPP7), was increased 2.7-fold. Spink3, a 
Kazal type 1 serine peptidase inhibitor, was decreased 
2.5-fold.  Serpina1a,  a  member  of  serine/cysteine Zhang et al
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  peptidase  inhibitors,  was  reduced  16-fold.  Alpha-
2-thiol  proteinase  inhibitor  (Kng1)  was  decreased 
29-fold.
Interestingly,  several  ion  regulation  genes  were 
found to be SRF-modulated genes. For instance, sev-
eral ion transport genes were down-regulated. ATP1a1 
was down 3-fold, slc4a8 was down 2.5-fold, TRPM7 
was  down  3-fold,  KCNQ2  was  down  3-fold,  and 
Sodium/bile acid co-transporter (slc10a) was down 
8-fold. Aqp4, a gene involved in water transport, was 
down 5-fold. Casq1, a calcium handling protein, was 
up 2.8-fold. The histidine rich calcium binding pro-
tein (HRC), which interacts with SERCA2, was down 
2.8-fold.36
All genes that were differentially expressed $2 
fold were validated with real-time RT-PCR and rep-
resentative results are depicted in Figure 5A and 5B. 
B4galnt1  (beta-1,4-n-acetyl-galactosaminyl  trans-
ferase 1), important in energy metabolism and the 
synthesis of gangliosides, was elevated 7 fold in the 
Mild-O-SRF Tg mouse hearts. Abnormalities in gan-
glioside metabolism maybe associated with Type I 
diabetes mellitus.37 Expression of Apod (Apolipopro-
teinD) a soluble lipid carrier is found in most human 
tissues, but especially in glia of the nervous system.38–41 
Its expression was increased 3.6 fold in the Mild-
O-SRF Tg (Fig. 5A). Acot9 was increased 2 fold in 
Mild-O-SRF Tg. Acyl CoA is important in triglycer-
ide synthesis and its increase can potentially increase 
cardiovascular  risk  profile  (Fig.  5A).42  CoasyCoA 
  synthase (CoASy) was decreased in the Mild-O-SRF 
Tg hearts (Fig. 5A). Coasyis a mitochondria-associated 
enzyme which mediates two final stages of de novo 
CoA biosynthesis.43 Pafah1b3 (platelet activating fac-
tor acetylhydrolase) and Pfkp (phosphofructokinase) 
which is involved in adiposity were also confirmed 
with qRT-PCR (Fig. 5A).44,45 Anxa10 was elevated 
more than 13 fold on q-RT-PCR (Fig. 5B).34,35
Altered expression of SRF-modulated 
genes was also observed in other mouse 
models of stress
SRF is a delayed immediate early response gene.46 
To  examine  whether  SRF-modulated  genes  might 
be  differentially  regulated  in  other  mouse  models 
of stress, we obtained cardiac gene expression data 
from  Gene  Expression  Omnibus  (GEO)  database. 
  Analysis  of  27  microarray  data  sets  representing 
various mouse models of cardiac stress revealed that 
many   SRF-modulated genes are indeed differentially 
regulated in response to stress, including the 194 SRF-
modulated genes reported in the present study. Further 
analysis revealed that most of the classic CArG SRF-
modulated genes (57 of 65) were also observed to be 
differentially expressed in these other mouse models 
(Table 3).
Of  those  SRF-modulated  genes  that  were  dif-
ferentially expressed in both the myocardial infarc-
tion (MI) model (GEO number: GDS488) and in the 
mild SRF transgenic model, the direction of change 
of these genes was similar at time points from 1 hr 
to 8 wks after MI (Table 3). At 1 hour after myocar-
dial infarction, the expression of periostin increased 
and expression of LOC547428 (predicted to be simi-
lar to T-cell receptor alpha chain) decreased, both in 
agreement with the changes seen in SRF-transgenic 
mice. At  four  hours,  the  expression  of  four  and  a 
half LIM domains 1 (Fhl1), serine (or cysteine) pep-
tidase inhibitor clade E member 1 (Serpine1), heat 
shock  protein  1B  (Hspa1b),  epithelial  membrane 
protein 1 (Emp1), and solute carrier family 20 mem-
ber 1 (Slc20a1) were increased, as they were also in 
SRF-transgenic mice. At one day post MI, natriuretic 
peptide precursor type A (Nppa) and Emp1 expres-
sion were increased as they were in SRF-transgenic. 
Expression of esterase 1 (Es1), intraflagellar transport 
81 homolog (Ift81) were similarly decreased between 
MI  and  SRF-Tg  models. At  seven  days  after  MI, 
expression  levels  of  Nppa,  Fhl1,  Serpine1,  Emp1, 
interferon  regulatory  factor  8  (Irf8),  and  periostin 
were increased, while those of interleukin 15 (Il-15) 
and Ift81 were decreased; all of these changes were in 
the same direction as those in the SRF-Tg model. At 
eight weeks after MI, the expression levels of myo-
sin heavy polypeptide 4 (Myh4) and UDP glucurono-
syltransferase  2  family  polypeptide  B5  (UGT2B5) 
were both down, and that of Emr1 was up, all of 
which were in agreement with those in the SRF-Tg 
  model.47 Thus, the SRF transgenic model shared cer-
tain similarities in ischemic stress signaling with that 
of the MI model. In the transverse aortic constriction 
(TAC) model (GEO number: GDS794), there were 
also interesting similarities.48 After two days of TAC, 
expression levels of Fhl1, RAB8B (a member of the 
RAS oncogene family) were increased, and that of 
Il-15 was decreased, all in the same direction as in Zhang et al
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the SRF-Tg model (Table 3). After ten days of TAC, 
  jagged 2 (Jag2), Il-15, Ift81, oncofetal antigen (Ofa), 
and aquaporin 4 (Aqp4) were down-regulated in the 
same direction as in the SRF-Tg model. After twenty-
one days of TAC, the expression levels of Fhl1, Ser-
pine1, Myh7, Emp1, and Periostin were up, and that 
of Ift81 was down, all of which were in agreement 
with the SRF-Tg model.48 Thus, the SRF transgenic 
model also shared certain similarities with the TAC 
model. These  data  suggest  that  common  signaling 
pathways mediating stress response may be involved 
in the regulation of SRF-modulated genes (Table 3).
Discussion
This study has several major findings. A set of 207 
SRF-modulated  genes  and  their  in  vivo  response 
to SRF regulation in the heart has been identified. 
Among them, 192 genes had CArG and/or CArG-like 
elements in their promoter regions. The 179 genes 
(51 of the 56 genes with classic CArG elements, and 
123 of the 136 genes with CArG-like elements) were 
not previously reported to have SRF binding sites.
The 207 SRF-modulated genes could be assigned to 
12 categories based on their function and Gene Ontol-
ogy term, suggesting that SRF regulates multiple cel-
lular functions via its target genes. Overexpression of 
SRF repressed 65% of the SRF-modulated genes. The 
gene profile revealed that in mild-SRF transgenic hearts, 
genes associated with cardiac energy metabolism shifted 
toward that of carbohydrate metabolism and away from 
that of fatty acid metabolism. It also revealed decreased 
expression of many genes that regulate transcriptional 
activity, stress response, protein turnover and ion regu-
lation. However, the expression of cytoskeletal genes 
was  considerably  increased.  Overall,  the  changes  in 
cardiac gene expression are similar to those that are 
observed during adult aging. These findings support the 
notion that an elevation of SRF protein level in typical 
adult aging may contribute to the altered cardiac struc-
ture and function observed during senescence.6
It is likely that SRF overexpression contributed to the 
altered energy metabolism in the mild-SRF transgenic 
heart. In the heart, energy usually comes from beta-
  oxidation of fatty acids and glycolysis, the proportion 
of which changes during different stages of life.   During 
fetal life, myocardial ATP is derived predominantly 
from glycolysis and lactate oxidation. After birth, a 
rapid increase in fatty acid oxidation occurs along with 
a decline in glycolytic and lactate oxidative rates.49 In 
the healthy adult heart, about 60%–90% of the ATP gen-
eration in the mitochondria comes from beta-oxidation 
of fatty acids, and the rest comes from pyruvate that is 
derived from glycolysis and lactate.50 A decline in fatty 
acid oxidation together with an increase in carbohy-
drate metabolism has been observed in the senescent 
heart.51–53 The changes in gene expression of the aged 
heart  include  an  up-  regulation  of  phosphofructoki-
nase, an allosteric enzyme that controls the rate of gly-
colysis by converting fructose 6-phosphate to fructose 
1,6-  bisphosphate, and down-regulation of solute car-
rier family 27 (slc27a1), which catalyzes the transfer of 
long-chain fatty acids across the plasma membrane.28,51 
In the mild-SRF transgenic heart, the up-regulation of 
phosphofructokinase  together  with  down-regulation 
of several proteins, including solute carrier family 27 
(slc27a1),28  carnitine  acetyltransferase,54  long-chain 
acyl-CoA synthetase 1 (ASCL1),55 lipase, and elon-
gase 2 (Elovl2),30 indicate that a reduction in fatty acid 
metabolism also occurred in the present SRF model. 
This shift away from fatty acid toward carbohydrate 
metabolism also occurs at certain disease stages and/
or in some experimental models of diabetes and heart 
failure.56,57  SRF  has  also  been  reported  to  mediate 
glucose response via their binding sites in the human 
nuclear receptor LXRbeta gene.58
Aging is associated with altered transcriptional and 
translational regulation.3,53,59 During the typical aging 
process, most components of the cardiovascular sys-
tem undergo gradual change, including a progressive 
loss of myocytes with subsequent hypertrophy of the 
remaining viable myocytes. The net result is a change 
in the ratio of myocytes to fibroblasts. As myocytes 
are lost and fibroblasts continue to divide and produce 
collagen, the physical properties of the aging heart 
become altered.3 From the point of view of molecular 
biology, a “selective” decline in gene expression is 
a common feature of aging in various tissues across 
species.59 A  number  of  studies  have  demonstrated 
that during adult aging, a majority of the genes are 
downregulated  in  various  tissues,  including  heart, 
kidney, prostate, oocytes and monocytes.52,53,60,61,63–65 
However, expression of a minority of the genes is 
actually  increased  with  age.  For  instance,  a  num-
ber  of  cytoskeletal  and  ECM  proteins  are  usually Zhang et al
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Table 3. comparison of expression of the SRF-modulated genes containing classic cArG elements between mild over-
expression SRF transgenic mouse and other mouse models. The cardiac gene microarray data of 27 experiments were 
downloaded from the Gene expression Omnibus (GeO) database. The expression of SRF-modulated genes was com-
pared among mild-SRF transgenic (Tg) mice and other mouse models in the GeO database that used the same Affymetrix 
gene chip as in our experiment. The majority of these mouse models used in comparison also had hemodynamic, ischemic 
or exercise induced stress. The results indicate that 13 genes (in pink) in other mouse models were either up-regulated 
or down-regulated in the same direction as that in the mild-SRF Tg mouse (labeled as “A” for agreement in the direction 
of change with the SRF Tg mouse). There were 20 genes (in purple) that showed a mixed pattern of being either “up- or 
down-regulated” (labeled as “A” for agreement or “D” for disagreement in the direction of change with the SRF Tg mouse) 
in the various models compared with the SRF Tg mouse. The other 15 genes (in light blue) were allaltered in the opposite 
direction to that which was observed in the mild-SRF Tg mouse (“D” for disagreement).
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cwf19l1* ↓ A ↓ A ↓ 100
AA930519 ↓ A ↓ 100
Mup1* ↓ A ↓ 100
Myh4* ↓ A ↓ A ↓ A ↓ A ↓ A ↓ 100
nppa ↑ A ↑ A ↑ A ↑ A ↑ 100
Jag2* ↓ A ↓ 100
Fhl1 ↑ A ↑ A ↑ A ↑ A ↑ A ↑ A ↑ 100
il15 ↓ A ↓ A ↓ A ↓ A ↓ A ↓ 100
Serpine1* ↑ A ↑ A ↑ A ↑ 100
Pcsk5* ↓ A ↓ 100
hspa1b* ↑ A ↑ A ↑ 100
cyp2b10* ↑ A ↑ 100
es1* ↓ A ↓ 100
ift81* ↓ A ↓ A ↓ A ↓ A ↓ A ↓ A ↓ D ↑ D ↑ 75
Ofa* ↓ A ↓ A ↓ D ↑ 67
cdca5* ↓ A ↓ D ↑ 50
Lancl2* ↓ A ↓ D ↑ D ↑ 33
LOc547428* ↓ A ↓ D ↑ D ↑ 33
R3hcc1 ↑ D ↓ A ↑ D ↓ D ↓ 25
Tpm2 ↑ A ↑ A ↑ A ↑ A ↑ D ↓ 80
Myh7* ↑ A ↑ A ↑ A ↑ D ↓ 75
Myl1* ↑ A ↑ A ↑ D ↓ 67
Rab8b* ↑ A ↑ D ↓ D ↓ 33
emp1* ↑ A ↑ A ↑ A ↑ A ↑ A ↑ D ↓ D ↓ 71
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Table 3. comparison of expression of the SRF-modulated genes containing classic cArG elements between mild over-
expression SRF transgenic mouse and other mouse models. The cardiac gene microarray data of 27 experiments were 
downloaded from the Gene expression Omnibus (GeO) database. The expression of SRF-modulated genes was com-
pared among mild-SRF transgenic (Tg) mice and other mouse models in the GeO database that used the same Affymetrix 
gene chip as in our experiment. The majority of these mouse models used in comparison also had hemodynamic, ischemic 
or exercise induced stress. The results indicate that 13 genes (in pink) in other mouse models were either up-regulated 
or down-regulated in the same direction as that in the mild-SRF Tg mouse (labeled as “A” for agreement in the direction 
of change with the SRF Tg mouse). There were 20 genes (in purple) that showed a mixed pattern of being either “up- or 
down-regulated” (labeled as “A” for agreement or “D” for disagreement in the direction of change with the SRF Tg mouse) 
in the various models compared with the SRF Tg mouse. The other 15 genes (in light blue) were allaltered in the opposite 
direction to that which was observed in the mild-SRF Tg mouse (“D” for disagreement).
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ift81* ↓ A ↓ A ↓ A ↓ A ↓ A ↓ A ↓ D ↑ D ↑ 75
Ofa* ↓ A ↓ A ↓ D ↑ 67
cdca5* ↓ A ↓ D ↑ 50
Lancl2* ↓ A ↓ D ↑ D ↑ 33
LOc547428* ↓ A ↓ D ↑ D ↑ 33
R3hcc1 ↑ D ↓ A ↑ D ↓ D ↓ 25
Tpm2 ↑ A ↑ A ↑ A ↑ A ↑ D ↓ 80
Myh7* ↑ A ↑ A ↑ A ↑ D ↓ 75
Myl1* ↑ A ↑ A ↑ D ↓ 67
Rab8b* ↑ A ↑ D ↓ D ↓ 33
emp1* ↑ A ↑ A ↑ A ↑ A ↑ A ↑ D ↓ D ↓ 71
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Table 3. (Continued)
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emr1* ↑ A ↑ A ↑ D ↓ A ↑ D ↓ 60
irf8 ↑ A ↑ A ↑ D ↓ D ↓ A ↑ 60
Tbp* ↑ A ↑ D ↓ 50
Postn # ↑ A ↑ A ↑ A ↑ A ↑ A ↑ D ↓ A ↑ D ↓ 75
il1f5* ↓ A ↓ D ↑ 50
Aqp4* ↓ A ↓ D ↑ A ↓ A ↓ 75
Slc20a1* ↑ A ↑ A ↑ D ↓ 67
hpx* ↓ A ↓ D ↑ 50
Ugt2b5* ↓ A ↓ D ↑ 50
c77681* ↓ D ↑ D ↑ 0
Mup1* ↓ D ↑ 0
Anxa10* ↑ D ↓ 0
Dsc2* ↓ D ↑ D ↑ 0
epb4.2* ↑ D ↓ 0
crk* ↓ D ↑ D ↑ 0
il4* ↑ D ↓ 0
Aqr* ↑ D ↓ 0
Brca1* ↓ D ↑ 0
e2f3* ↓ D ↑ D ↑ 0
Slc4a8* ↓ D ↑ 0
Serpina1d* ↓ D ↑ D ↑ 0
cyp3a16* ↓ D ↑ 0
Akr1c6* ↓ D ↑ 0
elovl2* ↓ D ↑ D ↑ 0
100 100 100 100 100 100 100 100 83 80 76 75 75 67 57 50 50 50 45 45 43 33 0 0 0 0 0
Note: columns from left to right: The 1st column shows the gene symbol. The 2nd column (in yellow) shows the direction of alteration of genes in the mild 
over-expression SRF Tg hearts. columns 3–29 are a list of mouse models in the GeO database used for comparison. experimental systems (columns) 
and genes (rows) were sorted so that those with the highest percentage agreement with the SRF Tg mouse in differentially expressed genes were toward 
the upper-left corner of the table (Table 3). The last column of the right and the last row at the bottom provides the percentage agreement of differentially 
expressed genes in the various models with the SRF Tg model.effect of mild-overexpression of SRF on cardiac gene expression in vivo
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Table 3. (Continued)
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irf8 ↑ A ↑ A ↑ D ↓ D ↓ A ↑ 60
Tbp* ↑ A ↑ D ↓ 50
Postn # ↑ A ↑ A ↑ A ↑ A ↑ A ↑ D ↓ A ↑ D ↓ 75
il1f5* ↓ A ↓ D ↑ 50
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Slc20a1* ↑ A ↑ A ↑ D ↓ 67
hpx* ↓ A ↓ D ↑ 50
Ugt2b5* ↓ A ↓ D ↑ 50
c77681* ↓ D ↑ D ↑ 0
Mup1* ↓ D ↑ 0
Anxa10* ↑ D ↓ 0
Dsc2* ↓ D ↑ D ↑ 0
epb4.2* ↑ D ↓ 0
crk* ↓ D ↑ D ↑ 0
il4* ↑ D ↓ 0
Aqr* ↑ D ↓ 0
Brca1* ↓ D ↑ 0
e2f3* ↓ D ↑ D ↑ 0
Slc4a8* ↓ D ↑ 0
Serpina1d* ↓ D ↑ D ↑ 0
cyp3a16* ↓ D ↑ 0
Akr1c6* ↓ D ↑ 0
elovl2* ↓ D ↑ D ↑ 0
100 100 100 100 100 100 100 100 83 80 76 75 75 67 57 50 50 50 45 45 43 33 0 0 0 0 0
Note: columns from left to right: The 1st column shows the gene symbol. The 2nd column (in yellow) shows the direction of alteration of genes in the mild 
over-expression SRF Tg hearts. columns 3–29 are a list of mouse models in the GeO database used for comparison. experimental systems (columns) 
and genes (rows) were sorted so that those with the highest percentage agreement with the SRF Tg mouse in differentially expressed genes were toward 
the upper-left corner of the table (Table 3). The last column of the right and the last row at the bottom provides the percentage agreement of differentially 
expressed genes in the various models with the SRF Tg model.Zhang et al
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increased in both the old human and rodent hearts.53 
The altered gene expression observed during aging 
is dynamic and well-regulated.59 SRF overexpression 
in the heart also changed the expression of a group 
of genes involved in transcriptional and translational 
regulation. Increased expression of four and a half lim 
domains 1 (FHL1) indicates the presence of cardiac 
stress as seen in other mouse model.66 Altered expres-
sion of TATA box binding protein and the subunit of 
general  transcription  factor  are  likely  to  affect  the 
transcriptional initiation and efficiency, while altered 
expression of the subunit 3 of eukaryotic translation 
initiation factor 2 is likely to affect the translational 
process. Altered expression of ribosomal proteins S4, 
S12, S17, and L34, are likely to affect mRNA splicing, 
ribosome assembly, translational fidelity and protein 
synthesis.67,68  Altered  expression  of  ribonucleotide 
reductase  m1  and  thymidine  kinase  1  could  affect 
DNA synthesis and repair, nucleotide metabolism as 
well as cell-cycle progression.69
Comparing  our  data  from  mild-SRF  transgenic 
mice with those in aged mice in the literature, it is 
found that they share similarities in terms of cardiac 
gene expression.51,53 Similar to that in aged mice, the 
majority of cardiac genes in most of the functional 
categories  were  decreased  in  the  transgenic  mice, 
whereas  cytoskeletal  genes  were  increased  in  the 
transgenic mice. Some well studied ECM proteins, 
including collagen I, were also significantly increased 
in the mild-SRF transgenic mouse model as well as in 
old age. Genes such as Apod, increased in our trans-
genic mouse, have also been shown to be increased in 
Alzheimer’s disease, Parkinson’s, stroke and schizo-
phrenia. In Alzhemer’s disease, it can be found in 
amyloid plaques within the brains of patients.38–41 It is 
possible that an increase in Apod is a compensatory 
mechanism in degenerative diseases as well as aging 
as it is involved in membrane lipids and degradation 
pathways.38–41
The most interesting comparison was between our 
SRF Tg model with mild over-expression of SRF and 
the  dominant  negative  PI3kinase  (dnPI3K)  model 
(Table 3, second to the last column on the right). The 
hearts of the dnPI3K model had a 100% disagreement 
in the direction of gene change when compared with 
the differentially expressed genes in hearts of the SRF 
Tg model (Table 3, last column and bottom row). 
This is notable because the dnPI3K mouse model has 
been reported by various investigators as being anti-
hypertrophic and even anti-cardiac aging,70,71 whereas 
the  SRF  Tg  model  with  mild  over-expression  of 
SRF is an model of cardiac aging.6 Hence, the data 
in Table 3, especially as it pertains to PI3K, further 
validates our model of cardiac aging with mild over-
expression of SRF in the heart. Although suppression 
of PI3K has been reported to prevent cardiac aging, 
a recent study suggests that dominant negative PI3K 
mice are more susceptible to congestive heart failure 
after myocardial infarction.72 However, variation in 
these studies could be explained by differences in the 
temporal expression of the transgene during develop-
ment and adulthood, compensatory gene responses as 
well as strain differences in mice.73
The present in vivo mouse model revealed many 
previously unreported SRF- modulated genes. The 
effect of SRF on gene expression has been studied 
both in vitro and in vivo. The in vitro transfection 
assay using cell lines has been frequently utilized 
to study the effect of SRF on the expression of a 
number  of  SRF-modulated  genes.74,75  Since  many 
cell lines that are used in the assay may not have the 
same SRF cofactors as that in cardiac myocytes and 
fibroblasts, the experimental data in cell lines may 
differ from that in the intact heart. The cardiac-spe-
cific mild-SRF transgenic mouse provides us with an 
excellent tool to identify new SRF-modulated genes 
and to study the response of these novel genes to 
cardiac SRF overexpression. Interestingly, most of 
the cardiac genes that responded significantly to SRF 
overexpression  contained  CArG  and/or  CArG-like 
elements  in  their  promoters.  The  down-regulation 
of a majority of SRF-modulated genes and up-regu-
lation of a minority of SRF-modulated genes in the 
present study support the notion that SRF-dependent 
gene regulation is complex. SRF-modulated genes 
are  regulated  by  multiple  transcription  regulators 
including SRF, SRF cofactors, SRF isoforms and a 
number of microRNAs.5,11,75–79 Other mechanisms of 
gene regulation include nonsense-mediated mRNA 
decay.80
Taken together, our findings demonstrate that a mild 
elevation of the SRF protein level that is observed in 
the rodent heart during typical adult aging may have a 
major impact on many cardiac genes, thereby affect-
ing multiple aspects of cardiac structure, metabolism 
and performance in old age.effect of mild-overexpression of SRF on cardiac gene expression in vivo
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